Export 92 results:
Author Title [ Type(Desc)] Year
Filters: Author is Pedro Rosa-Neto  [Clear All Filters]
Journal Article
Cyr M, Parent MJ, Mechawar N, Rosa-Neto P, Soucy J-P, Clark SD, Aghourian M, Bedard M-A.  2015.  Deficit in sustained attention following selective cholinergic lesion of the pedunculopontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [¹⁸F]fluoroethoxybenzovesamicol.. Behav Brain Res. 278:107-14.
Mechling AE, Arefin T, Lee H-L, Bienert T, Reisert M, Ben Hamida S, Darcq E, Ehrlich A, Gaveriaux-Ruff C, Parent MJ et al..  2016.  Deletion of the mu opioid receptor gene in mice reshapes the reward-aversion connectome.. Proc Natl Acad Sci U S A. 113(41):11603-11608.
Zimmer ERigon, Leuzy A, Gauthier S, Rosa-Neto P.  2014.  Developments in Tau PET Imaging.. Can J Neurol Sci. 41(5):547-53.
Chamoun M, Huppé-Gourgues F, Legault I, Rosa-Neto P, Faubert J, Vaucher E.  2015.  Does donepezil improve visual stimuli detection and perceptivo-cognitive performance of heathy young adults ? J Vis. 15(12):1133.
Cristini J, Weiss M, Heras BDe Las, Medina-Rincón A, Dagher A, Postuma RB, Huber R, Doyon J, Rosa-Neto P, Carrier J et al..  2020.  The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis.. Sleep Med Rev. 55:101384.
Benedet AL, Labbe A, Lemay P, Zimmer ER, Pascoal TA, Leuzy A, Mathotaarachchi S, Mohades S, Shin M, Dionne-Laporte A et al..  2015.  Epistasis analysis links immune cascades and cerebral amyloidosis.. J Neuroinflammation. 12:227.
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Bailey JJ, Kaiser L, Lindner S, Wüst M, Thiel A, Soucy J-P, Rosa-Neto P, Scott PJH, Unterrainer M, Kaplan DR et al..  2019.  First-in-Human Brain Imaging of [F]TRACK, a PET tracer for Tropomyosin Receptor Kinases.. ACS Chem Neurosci. 10(6):2697-2702.
Henriques ADallanora, Benedet ALessa, Camargos EFrancisco, Rosa-Neto P, Nóbrega OToledo.  2018.  Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.. Exp Gerontol.
Therriault J, Pascoal TA, Benedet AL, Tissot C, Savard M, Chamoun M, Lussier F, Kang MSu, Berzgin G, Wang T et al..  2021.  Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, ε4, and Cognitive Impairment.. Neurology. 96(7):e975-e985.
Paquin V, Therriault J, Pascoal TAli, Rosa-Neto P, Gauthier S.  2020.  Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging.. Cogn Behav Neurol. 33(4):288-293.
Ng KPin, Chiew HJin, Hameed S, Ting SKang Seng, Ng A, Soo SAnn, Wong BYX, Lim L, Yong ACW, Mok VCT et al..  2020.  Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research.. Alzheimers Dement (N Y). 6(1):e12085.
Knudsen GM, Ganz M, Appelhoff S, Boellaard R, Bormans G, Carson RE, Catana C, Doudet D, Gee AD, Greve DN et al..  2020.  Guidelines for the content and format of PET brain data in publications and archives: A consensus paper.. J Cereb Blood Flow Metab. 40(8):1576-1585.
Gauthier S, Leuzy A, Rosa-Neto P.  2014.  How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease? Neurodegener Dis. 13(2-3):197-9.
Bernard-Gauthier V, Mossine AV, Mahringer A, Aliaga A, Bailey JJ, Shao X, Stauff J, Arteaga J, Sherman P, Grand'Maison M et al..  2018.  Identification of [F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging.. J Med Chem. 61(4):1737-1743.
Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MSu, Beaudry T, Fonov VS, Gauthier S, Rosa-Neto P.  2017.  Identifying incipient dementia individuals using machine learning and amyloid imaging.. Neurobiol Aging. 59:80-90.
Leuzy A, Zimmer ERigon, Bhat V, Rosa-Neto P, Gauthier S.  2014.  Imaging biomarkers for amyloid: a new generation of probes and what lies ahead.. Int Psychogeriatr. 26(5):703-7.
Zimmer ER, Parent MJ, Leuzy A, Aliaga A, Aliaga A, Moquin L, Schirrmacher ES, Soucy J-P, Skelin I, Gratton A et al..  2015.  Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone.. J Cereb Blood Flow Metab. 35(7):1169-74.
Leuzy A, Zimmer ERigon, Dubois J, Pruessner J, Cooperman C, Soucy J-P, Kostikov A, Schirmaccher E, Désautels R, Gauthier S et al..  2015.  In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.. Brain Struct Funct.
Pascoal TA, Shin M, Kang MSu, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KPin, Hopewell R et al..  2018.  In vivo quantification of neurofibrillary tangles with [F]MK-6240.. Alzheimers Res Ther. 10(1):74.
Zimmer ERigon, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P.  2014.  In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals.. Transl Neurodegener. 3(1):6.
Meyer P-F, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M-É, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner JCS.  2019.  INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
Bernard-Gauthier V, Bailey JJ, Mossine AV, Lindner S, Vomacka L, Aliaga A, Shao X, Quesada CA, Sherman P, Mahringer A et al..  2017.  A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human.. J Med Chem. 60(16):6897-6910.
DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot M-C, Hall JA, Massarweh G, Soucy J-P, Rosa-Neto P et al..  2021.  Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia.. Neuroimage Clin. 29:102552.
Kwan ATian Hui, Arfaie S, Therriault J, Rosa-Neto P, Gauthier S.  2020.  Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials.. Dement Geriatr Cogn Disord. 49(4):334-348.